IJK
US Mid CapiShares S&P Mid-Cap 400 Growth ETF
iShares · Tracks S&P MidCap 400 Growth Index · Inception Jul 24, 2000
Composite score
Based on a 0.17% expense ratio.
Based on $11.30B in net assets.
Top-10 holdings represent 17.8% of net assets.
US Mid Cap base · ETF wrapper · 0.54% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use IJK in our tools
Tool · Cost
Compare IJK's fee against another fund
Compounds the 0.17% expense ratio against a peer over decades.
Tool · Overlap
Compare IJK's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar US Mid Cap funds.
Tool · TLH
Find a tax-loss harvesting partner for IJK
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | BlackRock Funds III | 4.65% |
| 2 | TechnipFMC plc | 1.71% |
| 3 | Casey's General Stores, Inc. | 1.65% |
| 4 | United Therapeutics Corp. | 1.57% |
| 5 | Curtiss-Wright Corp. | 1.54% |
| 6 | Flex Ltd. | 1.48% |
| 7 | XPO, Inc. | 1.40% |
| 8 | Woodward, Inc. | 1.31% |
| 9 | Royal Gold, Inc. | 1.26% |
| 10 | ATI, Inc. | 1.21% |
Compare IJK with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open IJK at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.